Press Release: Provectus Biopharmaceuticals, Inc. Reports Second Quarter 2016 Financial Results

Press Release: Provectus Biopharmaceuticals, Inc. Reports Second Quarter 2016 Financial Results

Provectus Biopharmaceuticals, Inc. Reports Second Quarter 2016 Financial Results

KNOXVILLE, Tenn.--(BUSINESS WIRE)--August 09, 2016-- 
 Stock Market Quotes, Business News, Financial News from http://commodity-market-news.com

Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, www.provectusbio.com), a clinical-stage oncology and dermatology biopharmaceutical company (“Provectus” or the “Company”) today announced its financial results for the quarter ended June 30, 2016.

Second Quarter Results and Balance Sheet Highlights

Our cash and cash equivalents were $4,891,313 at June 30, 2016, compared with $9,760,997 at March 31, 2016.

Shareholders’ equity at June 30, 2016 was $9,140,166. This compares to shareholders’ equity of $14,184,248 at March 31, 2016.

For additional information regarding Provectus’ results of operations and financial condition for the second quarter ended June 30, 2016, please see Provectus’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 9, 2016.

Management will host its 2016 second quarter business update conference call on Wednesday, August 10, 2016 at 4 pm Eastern Daylight Time. Management will provide a business update on PV-10 and PH-10 to the investment community and answer questions from investors.

Those who wish to participate in the conference call may telephone 877-407-4019 from the U.S. International callers may telephone 201-689-8337 approximately fifteen minutes before the call. A webcast will also be available at www.provectusbio.com.

A digital replay will be available by telephone approximately two hours after the completion of the call until November 30, 2016 and may be accessed by dialing 877-660-6853 from the U.S. or 201-612-7415 for international callers, and using the Conference ID # 13641484.

About Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer. Provectus’ investigational oncology drug, PV-10, is an ablative immunotherapy under investigation in solid tumor cancers. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company’s other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company’s website at www.provectusbio.com or contact Porter, LeVay & Rose, Inc.

FORWARD-LOOKING STATEMENTS: This release contains “forward-looking statements” as defined under U.S. federal securities laws. These statements reflect management’s current knowledge, assumptions, beliefs, estimates, and expectations and express management’s current views of future performance, results, and trends and may be identified by their use of terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements. Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date hereof, and we undertake no obligation to update such statements after this date.

Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2015) and the following:

   -- our determination, based on guidance from the FDA, whether to proceed 
      with or without a partner with the fully enrolled phase 3 trial of PV-10 
      to treat locally advanced cutaneous melanoma and the costs associated 
      with such a trial if it is necessary to complete (versus interim data 
      alone); 
 
   -- our determination whether to license PV-10, our investigational drug 
      product for melanoma and other solid tumors such as cancers of the liver, 
      if such licensure is appropriate considering the timing and structure of 
      such a license, or to commercialize PV-10 on our own to treat melanoma 
      and other solid tumors such as cancers of the liver; 
 
   -- our ability to license PH-10, our investigational drug product for 
      dermatology, on the basis of our phase 2 atopic dermatitis and psoriasis 
      results, which are in the process of being further developed in 
      conjunction with mechanism of action studies; and 
 
   -- our ability to raise additional capital if we determine to commercialize 
      PV-10 and/or PH-10 on our own, although our expectation is to be acquired 
      by a prospective pharmaceutical or biotech concern prior to 
      commercialization. 
 

View source version on businesswire.com: http://www.businesswire.com/news/home/20160809006464/en/

 
    CONTACT:    Provectus Biopharmaceuticals, Inc. 
 

Peter R. Culpepper, 866-594-5999 #30

Interim CEO, COO

or

Porter, LeVay & Rose, Inc.

Marlon Nurse, DM, 212-564-4700

SVP — Investor Relations

or

Allison + Partners

Todd Aydelotte, 646-428-0644

Managing Director — Media Relations